Taiwan Bio-Manufacturing Corporation (TBMC) is delighted to announce the election of Dr. Patrick Yang as its new Chairman of the Board. Dr. Yang is one of the most accomplished biotech manufacturing executives and technical operations leaders in the industry.  He brings an unparalleled depth of experience and knowledge to TBMC, further bolstering its position as a major player in the global CDMO industry.

With over four decades of leadership in technology, Dr. Yang’s illustrious career has seen him at the helm of various significant technological and operational advancements in some of the world’s most influential companies.  Dr. Yang is currently Vice Chairman at National Resilience Inc., where he plays a key role in steering the company’s strategic direction and growth.  From 2017 to 2019, Patrick Yang was executive vice president at Juno Therapeutics, a leading CAR-T biotech company (now part of BMS) based in Seattle.

Previously from 2009 to 2013, Patrick Yang was Global Head of Technical Operations at Roche Pharmaceutical based in Basel, Switzerland. He was previously Executive Vice President of Product Operations of Genentech from 2003 and assumed the role of Global Head of Technical Operations upon the acquisition of Genentech by Roche in 2009.

Dr. Yang is a member on the Board of Directors of public companies Acepodia, Sana Biotech and PharmaEssentia, as well as private companies National Resilience, AltruBio, and Antheia.

TBMC, a joint venture between Taiwan and National Resilience Inc., draws inspiration from the successful establishment of TSMC by combining the strengths of Resilience and Taiwan’s smart manufacturing prowess to create advanced biomanufacturing solutions. This partnership is poised to harness Taiwan’s leadership in digital manufacturing and the abundant life science talents, propelling TBMC to the forefront of the biomanufacturing industry.

The establishment of TBMC signifies a groundbreaking advancement in the CDMO sector, marking a new era in biomanufacturing innovation. Under Dr. Yang’s leadership, TBMC is poised to leverage Taiwan’s advanced digital manufacturing capabilities and its rich pool of life science talent to revolutionize the manufacturing of complex medicines. This initiative will enhance global healthcare by meeting the pressing needs for innovative and efficient therapeutic solutions.